Elder Pharma sets sight on the Rs. 800 crore for ‘Solo’ Inhalers

0
62

Elder Pharmaceuticals Limited has expanded its Solo range of OTC products with the launch of Solo range of inhalers for nasal congestion. The Solo basket comprises of Solo Rub, a pain balm, Solo Cough Drops and Solo lozenges for throat soothening. With an eye on the rural markets, the company is also launching these products in smaller sizes and has earmarked a budget of Rs. 25 crore for promotional activities.

Elder foresees an 8-10 per cent annual growth in the nasal decongestion market and is banking on substantial growth from Category B & C Towns. The market is presently valued at Rs. 800 crore with Vicks from P&G dominating with more than 50 per cent market share. Market for inhalation generic drugs is quite promising for India due to climate change and rapidly aging demographics where 22 per cent of population is above 55 years of age. Although the market leaders are everywhere, there is still a large untapped market in India and Elder is hoping to garner a 7 per cent share of the nasal decongestant market by FY2018.

Says Alok Saxena, Managing Director, Elder Pharmaceuticals Ltd, “Over the counter inhalers are the first level treatment for nasal congestion and doctors / specialists are consulted only if the condition worsens. Rising cost of raw materials, competitive market conditions and over dependency on the urban markets had affected the sales of the company’s OTC products in the recent years. With focus on Price, product mix and penetration, Elder is set to regain its prime position in the OTC sector.”

The market for Cough & Cold care solutions too witnessed a growth of 10 per cent during 2013-14 due to increasingly erratic weather, whereby the temperature kept switching from hot and humid to cold and rainy, further increasing seasonal health problems such as, cough, cold and allergies. It is for this reason that the company has also introduced Solo lozenges in Polypack for better visibility and customer use.